AusperBio Begins Clinical Trials for Groundbreaking HBV Treatment AHB-171

AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd., collectively known as AusperBio, have marked a significant milestone in the fight against chronic hepatitis B (CHB) by announcing the first patient dosing in their clinical study for AHB-171. This investigational therapeutic candidate leverages innovative hepatocyte-targeted small interfering RNA (siRNA) technology designed specifically for CHB treatment. This announcement is pivotal as it represents the advancement of AusperBio's second clinical-stage candidate, following the promising lead program AHB-137, contributing further to the company's expanding pipeline of hepatitis B virus (HBV) treatments.

The global prevalence of chronic hepatitis B presents a formidable health challenge, with the World Health Organization (WHO) estimating roughly 254 million individuals living with HBV as of their 2024 Global Hepatitis Report. Annually, the virus contributes to about 1.2 million new infections. Although existing antiviral therapies can suppress viral replication effectively, achieving a functional cure remains an unmet medical need that this innovative trial aims to address.

Dr. Guofeng Cheng, Co-founder and CEO of AusperBio, expressed how significant this milestone is, remarking on the company's capability to translate proprietary platform technologies into tangible clinical outcomes. AHB-171 enhances AusperBio's focus on differentiated oligonucleotide therapeutics. Cheng emphasized the importance of combining varied mechanisms of action in therapeutic strategies to aim for a successful functional cure for chronic hepatitis B.

Dr. Chris Yang, Co-founder and Chief Scientific Officer, also commented on AHB-171's unique integration of siRNA discovery with Au-HALO™, the company's proprietary liver-targeting delivery technology. This integration is expected to yield robust suppression of viral gene expression, propelling the overall efficacy of the treatment. The current clinical trial aims to evaluate AHB-171's performance specifically in CHB patients and validate the effectiveness of the Au-HALO™ targeting technology, further substantiating AusperBio's commitment to pioneering in the biopharmaceutical space.

Understanding AHB-171

AHB-171 is being developed with a laser focus on chronic hepatitis B, utilizing the sophisticated Au-HALO™ platform that targets liver cells. The candidate aims to selectively diminish viral gene expression, proposing a substantial antiviral impact with prolonged activity. As the first candidate generated under the Au-HALO™ banner, AHB-171 seeks to provide undeniable clinical proof of AusperBio's delivery technology and siRNA platform, while simultaneously diversifying the HBV therapeutic landscape.

About AusperBio

Established with operations across the USA and China, AusperBio is a near-commercial biopharmaceutical firm dedicated to advancing oligonucleotide and targeted therapy technologies to transform chronic hepatitis B into a manageable condition. The company has curated a versatile innovation ecosystem, prioritizing the implementation of its proprietary Med-Oligo™ antisense oligonucleotide (ASO) and Au-HALO™ delivery technologies to fuel the discovery and development of unique therapeutic options across various modalities. With several clinical-stage initiatives underway and a burgeoning preclinical pipeline, AusperBio aims to fulfill significant unmet medical needs and pave the way for broader applications of their therapies across different diseases.

In summary, the initiation of the AHB-171 study represents a hopeful advancement in the quest for effective treatments of chronic hepatitis B. The integration of novel drug discovery technologies not only reinforces AusperBio's innovative position but holds the promise of changing the lives of millions plagued by this viral infection. The journey, guided by collaborative efforts from patients and medical professionals, is just beginning as AusperBio works toward the goal of achieving a functional cure for chronic hepatitis B.

For more details about this groundbreaking work, visit www.ausperbio.com.